Odevixibat as an adjunctive treatment for refractory pruritus in rare variants of cholestatic liver disease.

OBJECTIVES

Odevixibat, a reversible ileal bile acid transport inhibitor, has been shown to reduce serum bile acids (sBA) and pruritus mostly in children with progressive familial intrahepatic cholestasis (PFIC) 1 and 2 in clinical trials and case reports. There are currently no published case reports or series describing its use in rare variants of cholestatic liver disease.

METHODS

We describe three children with progressive cholestatic liver disease who developed refractory pruritus, who had a genotypic diagnosis of , variant, and and variants; all being variants of unknown significance as per the American College of Medical Genetics and Genomics guidelines.

RESULTS

On Odevixibat there was a significant improvement in sBA (absolute change from baseline: -196 and -393 μmol/L) and pruritus in two children with heterozygous and mutations. The child with variants was found to have features of sclerosing cholangitis along with a diagnosis of Crohn's disease, which represents the first reported usage of Odevixibat in such a case with good response. There was some reported improvement in the third child with and variants; however, we hypothesize that no sustained improvement could be due to severe and progressive nature of the disease. There were no side effects reported and it was well tolerated in all.

CONCLUSION

We suggest that Odevixibat may be used as an adjunctive drug in refractory pruritus and could be started early in the course of disease if clinically and phenotypically indicated.